Jamie Brackenrich
Family · Roanoke, VANPI 1356953053
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,544 of the $39,855 with a category attached, or 76.6%. AbbVie accounts for 70.7% of it on its own, with 39 other manufacturers making up the rest. 2025 is the largest year on record at $10,842, 9.7 times the $1,120 reported in 2021. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 498 payments — averaging $80.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$28K
- Pfizer$7K
- Lundbeck LLC$795
- Biogen$641
- UCB, Inc.$480
- Argenx US, Inc.$407
- plus $3K from 34 others
What the payments were for
- Consulting fees$1,1553%
- Speaking & faculty fees$30,54477%
- Travel & lodging$4601%
- Food & beverage$7,59219%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 200 | $28,187 |
| Pfizer | 21 | $6,635 |
| Lundbeck LLC | 16 | $795 |
| Biogen | 49 | $641 |
| UCB, Inc. | 35 | $480 |
| Argenx US, Inc. | 21 | $407 |
| Teva Pharmaceuticals USA, Inc. | 19 | $306 |
| Lilly USA, LLC | 19 | $250 |
| AstraZeneca | 8 | $237 |
| Amgen | 16 | $217 |
| Biohaven Pharmaceutical Holding Company Ltd. | 19 | $190 |
| Sanofi | 5 | $171 |
| EMD Serono, Inc. | 9 | $137 |
| Novartis | 6 | $96 |
| Neurelis, Inc. | 5 | $90 |
| Irhythm Technologies, Inc. | 1 | $88 |
| SK Life Science, Inc. | 4 | $79 |
| CSL Behring | 4 | $79 |
| Genentech USA, Inc. | 3 | $74 |
| Neurocrine Biosciences, Inc. | 3 | $65 |
| GE HealthCare | 3 | $60 |
| Amneal Pharmaceuticals LLC | 3 | $60 |
| Biohaven Pharmaceuticals, Inc. | 3 | $50 |
| Hospira, Inc. | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| Medtronic | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| Impel Pharmaceuticals Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $38 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Acadia Pharmaceuticals Inc | 2 | $28 |
| TG Therapeutics, Inc. | 1 | $25 |
| Cala Health, Inc. | 1 | $21 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $15 |
| Eisai Inc. | 1 | $14 |
| Abbott | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Metacel Pharmaceuticals LLC | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$17,862
- QULIPTA$14,918
- NURTEC ODT$6,334
- VYEPTI$604
- BOTOX$124
- VYVGART HYTRULO$123
How this compares
$39,855 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 12 | $176,946 |
| TecfideraDimethyl Fumarate | 12 | $111,524 |
| Aimovig AutoinjectorErenumab-Aooe | 49 | $51,051 |
| QuliptaAtogepant | 21 | $24,992 |
| Emgality PenGalcanezumab-Gnlm | 24 | $16,677 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 15 | $10,883 |
| RytaryCarbidopa/Levodopa | 17 | $9,516 |
| EliquisApixaban | 11 | $7,644 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 117 | $3,166 |
| Dimethyl Fumarate | 11 | $1,763 |
| Temazepam | 15 | $1,584 |
| RizatriptanRizatriptan Benzoate | 70 | $1,517 |
| Levetiracetam | 80 | $1,188 |
| Propranolol Hcl ErPropranolol Hcl | 46 | $1,177 |
| Carbamazepine | 38 | $1,073 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $306 | $176,94612 claims |
| BiogenTecfidera | $641 | $111,52412 claims |
| AbbVieQulipta | $28,187 | $24,99221 claims |
| Amneal Pharmaceuticals LLCRytary | $60 | $9,51617 claims |
| PfizerEliquis | $6,635 | $7,64411 claims |
| Upsher-smith Laboratories LLCTopiramate | $16 | $73561 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.
Other family in Roanoke
- Pamela PriceRoanoke$13K
- Jessica SaundersRoanoke$12K
- Andrea CottonVirginia Beach$696K
- Susan MooreWytheville$438K
- Ellen WermterCharlottesville$251K
- Dana StallingsFranklin$225K
- Jocelyn BrackettHerndon$199K
- Hochong Smith GillesRichmond$131K
- Sean OlaughlinMidlothian$110K
- Adam MedlinHampton$67K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.